Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. Axitinib is marketed under the name Inlyta®, and if one previous systemic therapy for kidney cell cancer has failed, axitinib is indicated. The IC50 numbers reported for Axitinib are sub to low nanomolar in range.
Product Specification
| Alternative Name: | AG-013736 |
| |
| Formula: | C22H18N4OS |
| |
| MW: | 386.5 |
| |
| CAS: | 319460-85-0 |
| |
| Purity: | ≥95% (HPLC) |
| |
| Identity: | Determined by EM-MS, NMR |
| |
| Appearance: | Beige powder. |
| |
| Solubility: | Soluble in DMSO (42mg/ml) or ethanol (1mg/ml). |
| |
| Shipping: | Ambient |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
